Answers are grounded in this paper and cite their sources.
The introduction of direct-acting antivirals (DAAs) has significantly transformed the therapeutic landscape for chronic C hepatitis virus (HCV) infection. However, there is still room for further improvement in optimizing therapy efficacy and minimizing adverse effects.
No takes yet. Share an insight, caveat, or question.
Moriello et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: